Fig. 3

TO901317 improved neurobehavioral function but did not alter body weight or hemorrhage size after ICH. a There were no significant differences in body weight between the control (vehicle-treated) and 30 mg/kg TO901317-treated groups before or at 28 days after ICH. b Hemoglobin levels in vehicle-treated and TO901317-treated mice were not significantly different at 4 days post-ICH. Treatment with 30 mg/kg TO901317 (compared with vehicle) significantly c reduced the modified neurological severity score (mNSS) from 4 to 28 days (all P < 0.05), d improved the rotarod performance at 4, 14, 21, and 28 days (all P < 0.01), and e reduced the beam walk traversing time from 1 to 14 days (all P < 0.05) post-ICH. Values are mean ± SEM; ^# P < 0.05, ^## P < 0.01, and ^### P < 0.001 versus vehicle group (n = 13 mice/group, Student’s t test for body weight; n = 8 mice/group, Student’s t test for hemoglobin assay; n = 13 mice/group, repeated measures two-way ANOVA for behavioral tests)